Article
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
The lancet. Gastroenterology & hepatology - 1 Mar 2018
Grebely Jason, Dalgard Olav, Conway Brian, Cunningham Evan B, Bruggmann Philip, Hajarizadeh Behzad, Amin Janaki, Bruneau Julie, Hellard Margaret, Litwin Alain H, Marks Philippa, Quiene Sophie, Siriragavan Sharmila, Applegate Tanya L, Swan Tracy, Byrne Jude, Lacalamita Melanie, Dunlop Adrian, Matthews Gail V, Powis Jeff, Shaw David, Thurnheer Maria Christine, Weltman Martin, Kronborg Ian, Cooper Curtis, Feld Jordan J, Fraser Chris, Dillon John F, Read Phillip, Gane Ed, Dore Gregory J
Abstract excerpt
BACKGROUND: Despite revised guidelines that no longer exclude people who inject drugs (PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to treat recent PWID. This study aimed to evaluate the efficacy of sofosbuvir and velpatasvir therapy in people with chronic HCV infection and recent injection drug use. METHODS: In this open-label, single-arm phase 4 trial (SIMPLIFY), we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.